硼替佐咪皮下注射治疗多发性骨髓瘤的临床观察

Abstract
Figure/Table
References (19)
Related Citation (9)

Download: PDF (0 KB) HTML (25 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of subcutaneous injection Bortezomib treating multiple myeloma.Methods Clinical data of 46 patients with multiple myeloma treated in Department of internal medicine of hematology of our hospital from March 2012 to June 2017 were analyzed,and patients were divided into the two group according to the different treatment method.The control group(intravenous injection of Bortezomib,n=23)and observation group(subcutaneous injection of Bortezomib,n=23).The clinical curative effect,the incidence of adverse reactions of patients in the two group were observed.Results The total remission rate of observation group(78.3%)was higher than than that of the control group (56.5%),the incidence of adverse reactions was of observation group (8.7%)was lower than that of the control group (26.1%)(P＜0.05).Conclusion The total remission rate of clinical treatment of subcutaneous injection of Bortezomib treating multiple myeloma is high,and the incidence of adverse reaction is fewer.It is worthy of clinical promotion and application.The multiple myeloma patients by bortezomib hypodermic injection，clinical treatment total remission rate is high，adverse reactions rate is little，it is worth to be used.

Key words： Bortezomib Subcutaneous injection Intravenous injection Multiple myeloma

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Rong

Cite this article:

LI Rong. Clinical observation of subcutaneous injection of Bortezomib treating multiple myeloma[J]. 中国当代医药, 2018, 25(8): 40-42.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I8/40

[1]	李文君，郭艳秋，高玉娟，等.多发性骨髓瘤骨病的机制研究及治疗进展[J].实用肿瘤学杂志，2017，31（3）：246-249.
[2]	Kushlinskiǐ NE，Timofeev IuS，Gershteǐn ES，et al.Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].Vopr Onkol，2014，60（4）：413-421.
[3]	Colombo M，Mirandola L，Platonova N，et al.Notch－directed microenvironment reprogramming in myeloma：a single path to multiple outcomes[J].Leukemia，2013，27（5）：1009-1018.
[4]	Colombo M，Galletti S，Garavelli S，et al.Notch signaling deregulation in multiple myeloma：a rational molecular target[J].Oncotarget，2015，6（29）：26826-26840.
[5]	刘传才，陈文习.沙利度胺联合化疗治疗多发性骨髓瘤的临床观察[J].医学综述，2014，20（17）：3226-3227.
[6]	Hiasa M，Teramachi J，Oda A，et al.Pim－2 kinase is an important target of treatment for tumor progression and bone loss in myeloma[J].Leukemia，2015，29（1）：207-217.
[7]	周文锦，吴圣豪，石岳坚，等.硼替佐米不同途径给药治疗多发性骨髓瘤化疗后感染的研究[J].临床血液学杂志，2017，30（7）：543-544.
[8]	Rachner TD，Gobel A，Benad-Mehner P，et al.Dickkopf－1 as a mediator and novel target in malignant bone disease[J].Cancer Lett，2014，346（2）：172-177.
[9]	曲双，廖丽昇，魏天南，等.硼替佐米联合双膦酸盐对多发性骨髓瘤骨代谢指标的影响及意义[J].中国实验血液学杂志，2013，21（6）：1482-1485.
[10]	Chawla S，Henshaw R，Seeger L，et al.Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone：interim analysis of an open-label，parallel-group，phase 2 study[J].Lancet Oncol，2013，14（9）：901-908.
[11]	梁波，尹俊杰，王中良，等.两种剂量硼替佐米联合双膦酸盐治疗多发性骨髓瘤骨病临床对比研究[J].中国实验血液学杂志，2016，24（3）：769-772.
[12]	Wang JH，Zhang Y，Li HY，et al.Dickkopf-1 negatively regulates the expression of osteoprotegerin，a key osteoclas togenesis inhibitor，by sequestering Lrp6 in primary and metastatic lytic bone lesions[J].Medicine（Baltimore），2016，95（24）：e3767.
[13]	张碧霞，郭志强，翟英俊，等.感恩情绪护理对多发性骨髓瘤患者行血浆置换效果的影响[J].中国医学创新，2016，13（20）：86-89.
[14]	罗文丰，赵攀，魏锦，等.不同剂量硼替佐米BDT方案治疗新诊断多发性骨髓瘤的近期疗效及安全性[J].中国医学创新，2016，13（7）：7-11.
[15]	初晓丽，李铎.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床疗效[J].中国现代医生，2016，54（34）：73-75.
[16]	张颖颖，夏瑞祥.减低与标准剂量硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效对比分析[J].安徽医药，2015，19（5）：966-968.
[18]	况小红，童浩，苏寒，等.MP方案联合α-干扰素治疗多发性骨髓瘤临床分析[J].肿瘤基础与临床，2017，30（4）：292-294.
[17]	Ri M.Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy[J].Rinsho Ketsueki，2016，57（5）：537-545.
[19]	Pantani L，Zamagni E，Zannetti BA，et al.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma：analysis of long-term clinical outcomes[J].Ann Hematol，2013，93（1）：123-128.